Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
HANSOH PHARMA (03692.HK) Drug for Non-Small Cell Lung Cancer Included as Breakthrough Therapy
Recommend 2 Positive 2 Negative 0 |
||||
|
||||
|
HANSOH PHARMA (03692.HK) announced that on May 21 (yesterday), its self-developed fourth-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), HS-10504 tablets, was approved by the National Medical Products Administration for inclusion as a Breakthrough Therapy. The proposed indication is for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR C797S mutation following failure of prior EGFR-TKI therapy. (ha/da) Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
